AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement.
It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines.
AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US.
The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market - the world's largest, worth $635 billion - before Trump's return to office.
The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes.
Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay.
CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and "equalise" with other countries effectively contributing more to research and development costs.
"The US cannot build or carry the cost of R&D for the entire world," he said.
US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs.
"For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said Lutnick in a statement issued by AstraZeneca.
While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any levies take effect.
The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place.
The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said.
The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis and Sanofi.
Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies.
The new Virginia facility - the company's largest single manufacturing investment - will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said.
The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000.
In January it scrapped plans to invest £450m in its vaccine manufacturing plant in northern England, citing a cut in government support.
Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the US. The company declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 hours ago
- Irish Times
Possible tariff deal with US not a win for EU but does avoid damaging trade war
After months of back and forth and lots of shadow boxing, the European Union and the United States are said to be closing in on a trade deal that would impose a 15 per cent tariff on European imports. This would be similar to the agreement Donald Trump struck with Japan earlier this week and half the level threatened in recent weeks by the White House. On the face of it, such a deal might be considered a victory for the EU, limiting the damage for Irish and other European imports. There is talk of exclusions for medical devices and spirits, which would be of benefit to Ireland. READ MORE Yet a 15 per cent deal would be five percentage points higher than what the UK has agreed with Trump, putting Irish exporters at a disadvantage to their counterparts in Britain and north of the Border. It also means that some companies will have to consider raising their prices for a second time this year – a universal 10 per cent tariff has been in place since April 5th -or taking the tax hit themselves. Neither is an appealing scenario. [ US and EU close in on 15% tariff deal Opens in new window ] And it goes without saying that US consumers might baulk at the price of Kerrygold butter being increased again. There has to be a ceiling to what they are prepared to pay for a block of butter. Plus, what of the pharma sector (a key source of exports and corporation tax for Ireland), which has been separately threatened with tariffs of up to 200 per cent? Lots of details remain to be ironed out and a deal has yet to be signed, sealed and delivered. Trump might yet do another U-turn on negotiations. Anything is possible in the current uncertain climate. How will the updated National Development Plan shape Ireland in years to come? Listen | 35:59 But a deal would avoid a damaging trade war, and hopefully, draw a line under this saga. Irish and European businesses will also welcome some certainty on the tariffs issue, albeit at a cost to them, and an end to the swirl or rumour and uncertainty that has existed since Trump returned to power.
Irish Examiner
2 hours ago
- Irish Examiner
EU and US closing on 15% tariff deal to break impasse
The European Union and the US are progressing toward an agreement that would set a 15% tariff for most products, according to diplomats briefed on the negotiations. Member states could be ready to accept a 15% tariff and EU officials are pushing to have that cover sectors including cars, the diplomats said. Steel and aluminium imports above a certain quota would face the 50% duty, one of the diplomats added. The diplomats said that while the EU is optimistic that a deal can be reached, they are also cautious that any final agreement will need sign off from US president Donald Trump and his ultimate decision is difficult to predict. The EU has prepared plans to hit the US with 30% tariffs on some €100bn worth of goods in the event of no deal and if Mr Trump carries through with his threat to impose that rate on most of the bloc's exports after August 1. As a part of a first wave of countermeasures, the EU would combine an already approved list of tariffs on €21bn of US goods and a previously proposed list on an additional €72bn of US items into one package, a European Commission spokesman said yesterday. The US exports, which include industrial goods such as Boeing aircraft, US-made cars, and bourbon whiskey, would face a levy that matches Mr Trump's 30% threat, sources said. US treasury secretary Scott Bessent dismissed talk of €100bn tariffs by the EU as a 'negotiating tactic', adding: 'It's what I would do if I were in their place'. Mr Trump announced two tariff deals on Tuesday — one with the Philippines and another with Japan, and both featured across-the-board duties on their imports that were lower than initially threatened. Also noteworthy was the 15% US levy on Japanese autos that was lower than the current 25% rate on major car exporters including the EU. Mr Bessent said the EU has not yet brought anything as innovative as the Japanese offer. 'Talks are going better than they had been,' he said. 'I think that we are making good progress with the EU, but as I've said before, the EU has a collective action problem with 27 countries.' The EU's most potent trade tool is the ACI, and a growing number of member states is pushing for its use if a deal isn't reached. The instrument is primarily designed as a deterrent and is currently not on the table, with its activation requiring a qualified majority of member states to support the move. The ACI would enable the EU to launch a broad range of retaliatory actions, including new taxes on US tech giants, targeted curbs on investments, and limiting access to the EU market. The commission is discussing the instrument with members, the sources said. While some capitals having been pushing to use the tool, most want to wait to see how the situation develops beyond August 1 before progressing discussions further to try to achieve the required majority, they added. The overwhelming preferencewas to keep negotiations with Washington on track. European leaders are in Tokyo and Beijing this week for talks with some of the bloc's biggest trading partners in Asia. European automakers' stocks rallied after the US-Japan trade deal sparked hopes that American import tariffs on their vehicles could be cut. Bloomberg
Irish Times
2 hours ago
- Irish Times
US and EU close in on 15% tariff deal
The EU and US are closing in on a trade deal that would impose 15 per cent tariffs on European imports, similar to the agreement Donald Trump struck with Japan this week. Brussels could agree to the so-called reciprocal levies to avoid the US president's threat to raise them to 30 per cent from August 1st, three people familiar said. 'The Japan agreement made clear the terms of the shakedown,' said one EU diplomat. 'Most member states are holding their noses and could take this deal.' Both sides would waive tariffs on some products, including aircraft, spirits and medical devices, the people said. READ MORE [ Trump and Japan reach trade deal with tariff rate set at 15% Opens in new window ] The European Commission, which runs EU trade policy, briefed envoys from member states on Wednesday following talks with US counterparts. News of the prospective deal boosted the euro, which recouped earlier losses to trade flat on the day against the dollar. US stocks extended gains, with the S&P 500 up 0.6 per cent. The EU's exporters have been paying an additional 10 per cent tariff on goods sent to the US since April while talks between Washington and Brussels continued. That was on top of pre-existing duties averaging 4.8 per cent. The people said they understood the 15 per cent minimum tariff would include those existing duties, so Brussels views the deal as cementing the status quo. Tariffs on cars, which are currently 27.5 per cent, would therefore fall to 15 per cent. Two of the people said the deal struck between the US and Japan had pushed Brussels towards grudging acceptance of a higher reciprocal tariff rate to avert a damaging trade war. The EU could still retaliate if Trump tried to push further or followed through on his threat to raise reciprocal duties to 30 per cent from August. That could include activating its anti-coercion instrument (ACI) – its so-called trade bazooka. Never before used, it would give Brussels leeway to block US companies from public tenders, revoke intellectual property protection and restrict imports and exports. The bloc will continue to prepare a possible €93 billion package of retaliatory tariffs, set at up to 30 per cent, in case they could not agree a deal by August 1, the people added. A US official said the situation was fluid and subject to change. – Copyright The Financial Times Limited 2025
